AU2002306551A1 - Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5 - Google Patents

Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5

Info

Publication number
AU2002306551A1
AU2002306551A1 AU2002306551A AU2002306551A AU2002306551A1 AU 2002306551 A1 AU2002306551 A1 AU 2002306551A1 AU 2002306551 A AU2002306551 A AU 2002306551A AU 2002306551 A AU2002306551 A AU 2002306551A AU 2002306551 A1 AU2002306551 A1 AU 2002306551A1
Authority
AU
Australia
Prior art keywords
mrp5
treatement
modulators
tumor
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002306551A
Inventor
Anne Hollins Dantzig
Jennifer Diane Davidson
Christopher Alan Slapak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002306551A1 publication Critical patent/AU2002306551A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002306551A 2001-03-01 2002-02-28 Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5 Abandoned AU2002306551A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27253801P 2001-03-01 2001-03-01
US60/272,538 2001-03-01
US32661501P 2001-10-02 2001-10-02
US60/326,615 2001-10-02
PCT/US2002/005092 WO2002069950A2 (en) 2001-03-01 2002-02-28 Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5

Publications (1)

Publication Number Publication Date
AU2002306551A1 true AU2002306551A1 (en) 2002-09-19

Family

ID=26955587

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002306551A Abandoned AU2002306551A1 (en) 2001-03-01 2002-02-28 Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5

Country Status (2)

Country Link
AU (1) AU2002306551A1 (en)
WO (1) WO2002069950A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5683987A (en) * 1994-07-12 1997-11-04 The Board Of Regents Of The University Of Nebraska Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
US6162616A (en) * 1997-04-16 2000-12-19 Millennium Pharmaceuticals, Inc. Multidrug resistance-associated polypeptide
US6248752B1 (en) * 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy

Also Published As

Publication number Publication date
WO2002069950A3 (en) 2003-11-06
WO2002069950A2 (en) 2002-09-12
WO2002069950A8 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
AU2002325481A1 (en) Acrylic resin and antifouling coating
AU2002250331A1 (en) 7-pyrollyl tetracycline compounds and methods of use thereof
AU2002362436A1 (en) Modulators of lymphocyte activation and migration
AU2002255752A1 (en) 9-aminoacyl tetracycline compounds and methods of use thereof
AU2003256274A1 (en) Lens with colored portion and coated surface
AU2002315350A8 (en) Metathesis polymerization adhesives and coatings
AU2002314466A1 (en) Withasol and methods of use
SG123546A1 (en) Acrylic resin and antifouling coating
AU2003259717A1 (en) Modulators of rabggt and methods of use thereof
AU2002256990A1 (en) Apoptosis modulator bcl-b and methods for making and using same
AU3580001A (en) Modulators of the endocannabinoid uptake and of the vallinoid receptors
AU7757400A (en) Antiviral therapy use of p-glycoprotein modulators
AU7129700A (en) Ovarian tumor sequences and methods of use therefor
AU2002343724A1 (en) Adhesive and use thereof
AU2003285296A1 (en) Coumpounds modulating the activity of gapdh and/or iamt
AU2002233608A1 (en) Modulation of gsk-3beta activity and its different uses
AU2002302223A1 (en) Individualization of therapy with analgesics
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2002306551A1 (en) Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5
AU2003216354A1 (en) Modulators of paraptosis and related methods
AU2002244575A1 (en) Individualization of therapy with antidepressants
AU2003209879A1 (en) Vpr modulators and uses thereof
AU2002257411A1 (en) Individualization of therapy with antineoplastic agents
AU2002349225A1 (en) Individualization of therapy with antiviral agents
AU2002365707A1 (en) Use of elavl-1 gene in the detection and modulation of apoptosis

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase